HUE056866T2 - Herpes simplex vírus 2 eredetû csonka glikoprotein G - Google Patents

Herpes simplex vírus 2 eredetû csonka glikoprotein G

Info

Publication number
HUE056866T2
HUE056866T2 HUE17703097A HUE17703097A HUE056866T2 HU E056866 T2 HUE056866 T2 HU E056866T2 HU E17703097 A HUE17703097 A HU E17703097A HU E17703097 A HUE17703097 A HU E17703097A HU E056866 T2 HUE056866 T2 HU E056866T2
Authority
HU
Hungary
Prior art keywords
herpes simplex
simplex virus
truncated glycoprotein
glycoprotein
truncated
Prior art date
Application number
HUE17703097A
Other languages
English (en)
Inventor
Jan-Ake Liljeqvist
Original Assignee
Simplexia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Simplexia Ab filed Critical Simplexia Ab
Publication of HUE056866T2 publication Critical patent/HUE056866T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • G01N33/56994Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16071Demonstrated in vivo effect
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01DNA viruses
    • G01N2333/03Herpetoviridae, e.g. pseudorabies virus
    • G01N2333/035Herpes simplex virus I or II

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HUE17703097A 2016-02-01 2017-01-31 Herpes simplex vírus 2 eredetû csonka glikoprotein G HUE056866T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE1650122 2016-02-01

Publications (1)

Publication Number Publication Date
HUE056866T2 true HUE056866T2 (hu) 2022-03-28

Family

ID=57963202

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17703097A HUE056866T2 (hu) 2016-02-01 2017-01-31 Herpes simplex vírus 2 eredetû csonka glikoprotein G

Country Status (15)

Country Link
US (1) US10654899B2 (hu)
EP (1) EP3411388B1 (hu)
CN (1) CN108779151B (hu)
CA (1) CA3012267C (hu)
CY (1) CY1124824T1 (hu)
DK (1) DK3411388T3 (hu)
ES (1) ES2900364T3 (hu)
HR (1) HRP20211962T1 (hu)
HU (1) HUE056866T2 (hu)
LT (1) LT3411388T (hu)
PL (1) PL3411388T3 (hu)
PT (1) PT3411388T (hu)
RS (1) RS62747B1 (hu)
SI (1) SI3411388T1 (hu)
WO (1) WO2017134061A1 (hu)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0471778A1 (en) 1989-05-12 1992-02-26 Ciba Corning Diagnostics Corp. Herpes simplex virus type 2-glycoprotein g proteins and polypeptides
AU1273495A (en) 1994-12-06 1996-06-26 Bruschettini S.R.L. Glycoproteins from herpes virus and vaccines containing them
US5965354A (en) 1995-07-28 1999-10-12 Chiron Corporation Herpes simplex virus diagnostics
GB9615533D0 (en) 1996-07-24 1996-09-04 Peptide Therapeutics Ltd Diagnostic test for herpes simplex virus type-2
US6375952B1 (en) * 1998-08-07 2002-04-23 University Of Washington Immunological herpes simplex virus antigens and methods for use thereof
CN100560720C (zh) * 2001-03-28 2009-11-18 哈佛大学校长及研究员协会 将外源蛋白递送到胞质溶胶中的方法,及其用途
US8617564B2 (en) 2009-05-22 2013-12-31 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
US9968666B2 (en) * 2009-06-12 2018-05-15 Vaccine Technologies, Incorporated Methods and compositions for promoting a cell-mediated immune response
WO2012074881A2 (en) 2010-11-24 2012-06-07 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response

Also Published As

Publication number Publication date
SI3411388T1 (sl) 2022-02-28
DK3411388T3 (da) 2021-12-13
PL3411388T3 (pl) 2022-04-04
EP3411388A1 (en) 2018-12-12
WO2017134061A1 (en) 2017-08-10
CN108779151A (zh) 2018-11-09
EP3411388B1 (en) 2021-11-17
CA3012267A1 (en) 2017-08-10
PT3411388T (pt) 2021-12-20
HRP20211962T1 (hr) 2022-03-18
US10654899B2 (en) 2020-05-19
CY1124824T1 (el) 2022-11-25
ES2900364T3 (es) 2022-03-16
CN108779151B (zh) 2022-12-13
RS62747B1 (sr) 2022-01-31
LT3411388T (lt) 2022-01-10
CA3012267C (en) 2023-09-19
US20190031723A1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
IL258833A (en) Make simple shingles virus
EP3641810A4 (en) VACCINES AGAINST HERPES SIMPLEX VIRUS
IL263972A (en) Dihydropyranopyrimidines for the treatment of viral infections
IL267949A (en) Altered virus
HK1254293A1 (zh) 一種重組單純皰疹病毒及其用途
EP3113801A4 (en) Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
IL256327B (en) Pharmaceutical preparations for the treatment of viral problems of the eye
IL266095A (en) Validation of continuous viral clearance
IL267785A (en) virus
DK3469071T3 (da) Herpesvirus med modificeret glycoprotein D
GB201520345D0 (en) Herpes simplex viruses
EP3261654A4 (en) NON-SPECIFIC DELAYED TYPE HYPERSENSITIVITY RESPONSE FOR TREATMENT OF HERPES SIMPLEX VIRUS INFECTION
GB201820983D0 (en) Virus
EP3500280A4 (en) VIRUS Vaccines
LT3471732T (lt) Liposomos, skirtos virusinių infekcijų gydymui
PT3411388T (pt) Glicoproteína g truncada do vírus herpes simplex 2
SG10202010317VA (en) Pyrimidine prodrugs for the treatment of viral infections and further diseases
GB201707106D0 (en) Viral antigens
GB201813175D0 (en) Virus use
GB201707093D0 (en) Viral antigens
GB201818307D0 (en) HIV Vaccine
GB201818308D0 (en) HIV Vaccine
GB201716047D0 (en) Virus
GB201700259D0 (en) Virus
AU2016903295A0 (en) Viral Vaccines